$44.00−0.65 (−1.46%)
At close: Oct 1, 2026, 4:00 PM ET
Ionis Pharmaceuticals Inc · Overview
Industry: Drugs · see every company filed here →
Ionis Pharmaceuticals Inc scores 30/100. Weak. Value is the soft spot versus 400 Healthcare peers.
Tenet Score · vs sector
n=400Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value12
Quality31
Health50
Growth25
Factor grades
Grid rings: 25 · 50 · 75 · 100 percentile
ValueFQualityDHealthCGrowthFMomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Price
Loading chart…
P/E
—
no P/E on file
P/B
16.6×
cap ÷ Jun 30, 2026 book value, Oct 1, 2026 close
P/S
7.7×
price to fiscal 2025 sales
ROE
−105%
TTM through Jun 30, 2026
Operating margin
−40.4%
fiscal 2025, before interest and tax
Net margin
−64.7%
TTM through Jun 30, 2026
Current ratio
7.89
Jun 30, 2026 balance sheet
Net debt / EBITDA
—
negative EBITDA denominator
EPS CAGR 5y
—
needs five years of positive earnings
Market cap
$7.3B
mid cap
Div yield
0.00%
reinvests all
52-wk range
43.01 – 86.74
low → high
Market cap: share price × the latest quarter's diluted weighted-average share count (vendor).
The whole report, at a glance · every card is a live peek, click any to open the section
Tenets
0 / 17
- ✕ Buffett Quality
- ✕ Piotroski F-Score
- ✕ Graham Defensive
- ✕ Quality Compounder
- ✕ Drawdown Context
- ✕ Reversal Evidence
+11 more →
Financials
Revenue, margins and the five-year statements.Analyst Forecasts
Consensus estimates are on the Analyst tab.
Earnings
Report dates and the beat-versus-miss record.Statistics
ROIC−34%
Gross margin98%
Debt / equity3.60
Technical Analysis
Downtrend short-term signalvs 50-day−18.7%
vs 200-day−37.6%
RSI (14)31
News & Insights
Headlines are on the News tab.Dividends
0.00% yield
No dividend. Cash stays in the business.
Ownership
565 13F filers
Holdings are on file. The share count they would be divided by is unverified, so the percentage is withheld.
About Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of he…
Composite computed 2026-10-02 · peer basis: Healthcare (n=400) · every glimpse links to its full section with sources · not investment advice.
ETF exposure
Free account: the funds that hold IONS, and at what weight. Everything else on this page stays open.Create a free account